HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By



This article was originally published in The Rose Sheet

Executive Summary

Procter & Gamble Prestige Beauty Fine Fragrances and Clairol will be combined with Wella and Cosmopolitan Cosmetics under a unit to be overseen by Wella CEO Heiner Gurtler, P&G announces July 14. Gurtler is appointed group president-global prestige and professional care, reporting to P&G CEO A.G. Lafley. "This structure will ensure that Wella's prestige and professional care expertise is preserved and further developed," Gurtler notes. Wella distributes fragrances under Cosmopolitan Cosmetics. According to P&G, any changes to distribution of its prestige beauty or fragrance lines have not been established, but the company recently announced plans to terminate its U.S. fragrance distribution agreement with Clarins effective Dec. 31, 2005. In addition to Gurtler's appointment, P&G names Executive VP-Wella Professional, America/Asia/Pacific Carsten Fischer to the post of President-Professional Care, and Vice-President-Global Fine Fragrances Hartwig Langer to President-Prestige Products, both reporting to Gurtler...

You may also be interested in...

Wella To Appoint New CEO Following Gurtler’s Departure

Wella's supervisory board will name a new CEO in September to succeed Heiner Gurtler, who announced June 29 that he will step down as head of the Procter & Gamble division in October. The exec will simultaneously leave his position as P&G group president, global prestige and professional care

Regulatory Measures Could Mitigate EU Coronavirus Risks

As part of its response to the coronavirus outbreak, Medicines for Europe has set out a series of policy recommendations that it says could help to mitigate the risks of COVID-19.

EU Off-Patent Industry Sees ‘Limited Immediate Risk’ From COVID-19

 The coronavirus COVID-19 outbreak poses a “limited immediate risk” to European production and supplies of off-patent drugs, according to industry association Medicines for Europe. However, if the situation continues for an extended period an “important impact” cannot be ruled out.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts